Ligand ID: RLT


Drugbank ID:
DB06817
(Raltegravir)


Indication:
For the treatment of HIV-1 infection in conjunction with other antiretrovirals.

Get human targets for RLT in PDB (known and potential targets)

RESULTS FROM SUB-STRUCTURAL SIMILARITY SEARCHES MAPPED TO LIGAND 'RLT' AND SARS-COV-2 / COVID-19 STRUCTURES

1) User may click on the DrReposER ID (the first column) to get information on the binding sites and drug molecule.
2) Click View (the second last column) to view matched residues and superposition in the NGL viewer (upper right part).
3) User may also click on the Dock (the last column) to get script for molecular docking in UCSF Chimera throuh AutoDock Vina.

DrReposER ID / Desc. Hit
PDBID		 Hit
Macromolecule		 Res.
Matches		 View Interface RMSD Seq.
Identity (%)		 HETATM Dock
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4MDA_A_RLTA403_1
(MARINER MOS1
TRANSPOSASE)		5r80 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 6
ASP A 153
ASN A 151
TYR A 101
ASP A 155
1.51A21.20
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4MDB_A_RLTA401_1
(MARINER MOS1
TRANSPOSASE)		6m71 NSP12
(SARS-CoV-2)		4 / 6
ASN A  39
ALA A  43
TYR A 728
ASP A 711
1.71A12.58
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4MDA_A_RLTA403_1
(MARINER MOS1
TRANSPOSASE)		6m71 NSP12
(SARS-CoV-2)		4 / 6
ASP A 623
ALA A 625
TYR A 458
ASP A 452
1.61A12.58
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3L2V_A_RLTA397_1
(INTEGRASE)		6m71 NSP12
NSP7
(SARS-CoV-2)		4 / 7
ASP A 445
GLN C  18
TYR A 546
GLN A 408
1.52A18.47
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3OYA_A_RLTA398_1
(PFV INTEGRASE)		6m71 NSP12
(SARS-CoV-2)		4 / 8
ASP A 865
PRO A 834
TYR A 831
PRO A 868
1.57A18.47
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4MDB_A_RLTA401_1
(MARINER MOS1
TRANSPOSASE)		6m71 NSP12
(SARS-CoV-2)		4 / 6
ASP A 126
ALA A 130
TYR A 129
ASP A 208
1.67A12.58
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3OYA_A_RLTA398_1
(PFV INTEGRASE)		6m71 NSP12
NSP7
(SARS-CoV-2)		4 / 8
ASP A 445
GLN C  18
TYR A 546
GLN A 408
1.47A18.47
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4MDA_A_RLTA403_1
(MARINER MOS1
TRANSPOSASE)		6m71 NSP12
(SARS-CoV-2)		4 / 6
ASP A  36
ALA A  46
TYR A 129
ASP A 208
1.77A12.58
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4MDB_A_RLTA401_1
(MARINER MOS1
TRANSPOSASE)		6m71 NSP12
(SARS-CoV-2)		4 / 6
ASN A  39
ALA A  43
TYR A 728
ASP A 208
1.29A12.58
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4MDB_A_RLTA401_1
(MARINER MOS1
TRANSPOSASE)		6m71 NSP12
(SARS-CoV-2)		4 / 6
ASP A 221
ASN A  39
ALA A  43
TYR A 728
1.74A12.58
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4MDB_A_RLTA401_1
(MARINER MOS1
TRANSPOSASE)		6m71 NSP12
(SARS-CoV-2)		4 / 6
ASP A  36
ALA A  46
TYR A 129
ASP A 208
1.74A12.58
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4MDB_A_RLTA401_1
(MARINER MOS1
TRANSPOSASE)		6m71 NSP12
(SARS-CoV-2)		4 / 6
ASP A 618
ASN A 790
ALA A 625
TYR A 458
1.36A12.58
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4MDB_A_RLTA401_1
(MARINER MOS1
TRANSPOSASE)		6m71 NSP12
(SARS-CoV-2)		4 / 6
ASN A 507
ALA A 502
TYR A 515
ASP A 499
1.64A12.58
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3OYA_A_RLTA398_1
(PFV INTEGRASE)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
ASP A 614
GLN A 613
TYR A 612
GLN A 644
1.36A16.22
None
None
None
NAG  A1302 (-3.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3L2V_A_RLTA397_1
(INTEGRASE)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
TYR C1138
PRO C1143
GLN C1142
GLU C1144
1.42A16.22
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3OYA_A_RLTA398_1
(PFV INTEGRASE)		6vxs NSP3
(SARS-CoV-2)		4 / 8
ASP A 105
GLN A 107
PRO A  98
GLU A 104
1.70A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3L2V_A_RLTA397_1
(INTEGRASE)		6vxs NSP3
(SARS-CoV-2)		4 / 7
ASP A 105
GLN A 107
PRO A  98
GLU A 104
1.73A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3L2V_A_RLTA397_1
(INTEGRASE)		6vxs NSP3
(SARS-CoV-2)		4 / 7
ASP B 105
GLN B 107
PRO B  98
GLU B 104
1.71A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3OYA_A_RLTA398_1
(PFV INTEGRASE)		6vxs NSP3
(SARS-CoV-2)		4 / 8
ASP B 105
GLN B 107
PRO B  98
GLU B 104
1.76A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3L2V_A_RLTA397_1
(INTEGRASE)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
GLN A1106
TYR A1067
GLN A1071
GLU A1072
1.60A15.97
None
None
NAG  A1312 ( 4.4A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3OYA_A_RLTA398_1
(PFV INTEGRASE)		6w01 URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 8
GLN B 176
PRO B 158
TYR B 179
GLU B 192
1.70A20.32
None
EDO  B 407 ( 4.9A)
None
EDO  B 410 ( 3.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3OYA_A_RLTA398_1
(PFV INTEGRASE)		6w4h NSP16
(SARS-CoV-2)		4 / 8
ASP A6824
GLN A6826
PRO A7034
GLU A6971
1.60A23.21
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3OYA_A_RLTA398_1
(PFV INTEGRASE)		6w75 NSP16
(SARS-CoV-2)		4 / 8
GLN C6801
TYR C6851
PRO C6805
GLN C6847
1.80A16.20
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4MDA_A_RLTA403_1
(MARINER MOS1
TRANSPOSASE)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 6
ASP A  76
ASN A 156
ALA A 153
TYR A  83
1.75A20.32
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3OYA_A_RLTA398_1
(PFV INTEGRASE)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 8
PRO C 248
TYR C 264
PRO C 299
GLN C 250
1.62A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3OYA_A_RLTA398_1
(PFV INTEGRASE)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 8
PRO A 247
PRO A 299
GLN A 250
GLU A 263
1.32A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3OYA_A_RLTA398_1
(PFV INTEGRASE)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 8
PRO B 247
PRO B 299
GLN B 250
GLU B 263
1.31A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4MDA_A_RLTA403_1
(MARINER MOS1
TRANSPOSASE)		6wiq NSP8
(SARS-CoV-2)		4 / 6
ASP B 112
ASN B 108
ALA B 110
ASP B 134
1.74A19.74
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4MDA_A_RLTA403_1
(MARINER MOS1
TRANSPOSASE)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 6
ASP B 340
ASP B 343
ASN B 345
ALA E 267
1.61A20.98
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3OYA_A_RLTA398_1
(PFV INTEGRASE)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
ASP E 343
ASP E 340
PRO F 258
GLN F 260
1.70A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4MDA_A_RLTA403_1
(MARINER MOS1
TRANSPOSASE)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 6
ASP B 340
ASP B 343
ASN E 269
ALA E 267
1.80A20.98
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3OYA_A_RLTA398_1
(PFV INTEGRASE)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
GLN D 303
PRO D 302
TYR B 268
GLU D 290
1.37A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4MDB_A_RLTA401_1
(MARINER MOS1
TRANSPOSASE)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 6
ASP B 340
ASP B 343
ASN B 345
ALA E 267
1.76A20.98
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3OYA_A_RLTA398_1
(PFV INTEGRASE)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
ASP A 343
ASP A 340
PRO B 258
GLN B 260
1.75A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3OYA_A_RLTA398_1
(PFV INTEGRASE)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
GLN D 303
PRO D 302
TYR B 268
GLN D 294
1.71A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3OYA_A_RLTA398_1
(PFV INTEGRASE)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
ASP F 343
ASP F 340
PRO E 258
GLN E 260
1.78A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3OYA_A_RLTA398_1
(PFV INTEGRASE)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
ASP D 343
ASP D 340
PRO C 258
GLN C 260
1.72A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3OYA_A_RLTA398_1
(PFV INTEGRASE)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
ASP B 343
ASP B 340
PRO A 258
GLN A 260
1.70A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3OYA_A_RLTA398_1
(PFV INTEGRASE)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 8
GLN C6801
TYR C6851
PRO C6805
GLN C6847
1.78A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3OYA_A_RLTA398_1
(PFV INTEGRASE)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 8
GLN A6801
TYR A6851
PRO A6805
GLN A6847
1.77A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3OYA_A_RLTA398_1
(PFV INTEGRASE)		6wkq NSP16
(SARS-CoV-2)		4 / 8
GLN C6801
TYR C6851
PRO C6805
GLN C6847
1.77A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3OYA_A_RLTA398_1
(PFV INTEGRASE)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 8
ASP B 301
TYR B 194
GLN B 197
GLU B 211
1.79A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4MDA_A_RLTA403_1
(MARINER MOS1
TRANSPOSASE)		6wqd NSP8
(SARS-CoV-2)		4 / 6
ASP B 112
ASN B 108
ALA B 110
ASP B 134
1.74A19.74
None
EDO  B 301 (-4.3A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4MDA_A_RLTA403_1
(MARINER MOS1
TRANSPOSASE)		6wqd NSP8
(SARS-CoV-2)		4 / 6
ASP D 112
ASN D 108
ALA D 110
ASP D 134
1.67A19.74
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3OYA_A_RLTA398_1
(PFV INTEGRASE)		6wrh PEPTIDASE C16
(SARS-CoV-2)		4 / 8
PRO A 247
PRO A 299
GLN A 250
GLU A 263
1.48A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4MDA_A_RLTA403_1
(MARINER MOS1
TRANSPOSASE)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		4 / 6
ASP B 112
ASN B 108
ALA B 110
ASP B 134
1.80A19.57
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4MDB_A_RLTA401_1
(MARINER MOS1
TRANSPOSASE)		6yi3 NUCLEOPROTEIN
(SARS-CoV-2)		4 / 6
ASN A   8
ALA A  10
TYR A  71
ASP A 104
1.58A18.22
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3L2V_A_RLTA397_1
(INTEGRASE)		6yla LIGHT CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		4 / 7
ASP C  66
ASP E 364
TYR E 365
PRO E 527
1.78A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4MDA_A_RLTA403_1
(MARINER MOS1
TRANSPOSASE)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 6
ASP E 442
ASN E 354
ALA E 352
TYR E 351
1.73A20.49
None
DMS  E 905 (-4.5A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4MDA_A_RLTA403_1
(MARINER MOS1
TRANSPOSASE)		6yla LIGHT CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		4 / 6
ASP C  66
ASP E 364
ASN E 388
ALA E 363
1.72A24.03
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4MDA_A_RLTA403_1
(MARINER MOS1
TRANSPOSASE)		6yla LIGHT CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		4 / 6
ASP L  66
ASP A 364
ASN A 388
ALA A 363
1.57A24.03
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4MDA_A_RLTA403_1
(MARINER MOS1
TRANSPOSASE)		6ym0 SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 6
ASP E 442
ASN E 354
ALA E 352
TYR E 351
1.75A20.49
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4MDA_A_RLTA403_1
(MARINER MOS1
TRANSPOSASE)		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 6
ASP E 442
ASN E 354
ALA E 352
TYR E 351
1.73A20.08
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4MDA_A_RLTA403_1
(MARINER MOS1
TRANSPOSASE)		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 6
ASP A 442
ASN A 354
ALA A 352
TYR A 351
1.74A20.08
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4MDB_A_RLTA401_1
(MARINER MOS1
TRANSPOSASE)		7btf NSP12
(SARS-CoV-2)		4 / 6
ASP A  67
ASN A 215
ALA A  97
TYR A 217
1.59A12.58
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4MDB_A_RLTA401_1
(MARINER MOS1
TRANSPOSASE)		7btf NSP12
(SARS-CoV-2)		4 / 6
ASP A 126
ALA A 130
TYR A 129
ASP A 208
1.66A12.58
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3L2V_A_RLTA397_1
(INTEGRASE)		7btf NSP12
NSP7
(SARS-CoV-2)		4 / 7
ASP A 445
GLN C  18
TYR A 546
GLN A 408
1.70A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4MDB_A_RLTA401_1
(MARINER MOS1
TRANSPOSASE)		7btf NSP12
(SARS-CoV-2)		4 / 6
ASP A 221
ASN A  39
ALA A  43
TYR A 728
1.71A12.58
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4MDB_A_RLTA401_1
(MARINER MOS1
TRANSPOSASE)		7btf NSP12
(SARS-CoV-2)		4 / 6
ASP A 760
ASN A 790
ALA A 625
TYR A 458
1.64A12.58
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4MDB_A_RLTA401_1
(MARINER MOS1
TRANSPOSASE)		7btf NSP12
(SARS-CoV-2)		4 / 6
ASN A  39
ALA A  43
TYR A 728
ASP A 208
1.27A12.58
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4MDB_A_RLTA401_1
(MARINER MOS1
TRANSPOSASE)		7btf NSP12
(SARS-CoV-2)		4 / 6
ASP A  36
ALA A  46
TYR A 129
ASP A 208
1.79A12.58
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4MDB_A_RLTA401_1
(MARINER MOS1
TRANSPOSASE)		7btf NSP12
(SARS-CoV-2)		4 / 6
ASN A  39
ALA A  43
TYR A 728
ASP A 711
1.75A12.58
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4MDB_A_RLTA401_1
(MARINER MOS1
TRANSPOSASE)		7btf NSP12
(SARS-CoV-2)		4 / 6
ASN A 507
ALA A 502
TYR A 515
ASP A 499
1.66A12.58
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3OYA_A_RLTA398_1
(PFV INTEGRASE)		7btf NSP12
NSP7
(SARS-CoV-2)		4 / 8
ASP A 445
GLN C  18
TYR A 546
GLN A 408
1.57A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4MDB_A_RLTA401_1
(MARINER MOS1
TRANSPOSASE)		7btf NSP12
(SARS-CoV-2)		4 / 6
ASP A 618
ASN A 790
ALA A 625
TYR A 458
1.32A12.58
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4MDA_A_RLTA403_1
(MARINER MOS1
TRANSPOSASE)		7buy VIRUS MAIN PROTEASE
(SARS-CoV-2)		4 / 6
ASP A 289
ASN A 203
ALA A 129
ASP A 197
1.66A21.20
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3OYA_A_RLTA398_1
(PFV INTEGRASE)		7bv1 NSP12
NSP7
(SARS-CoV-2)		4 / 8
ASP A 445
GLN C  18
TYR A 546
GLN A 408
1.53A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4MDB_A_RLTA401_1
(MARINER MOS1
TRANSPOSASE)		7bv1 NSP12
(SARS-CoV-2)		4 / 6
ASP A 126
ALA A 130
TYR A 129
ASP A 208
1.66A12.85
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4MDB_A_RLTA401_1
(MARINER MOS1
TRANSPOSASE)		7bv1 NSP12
(SARS-CoV-2)		4 / 6
ASP A 618
ASN A 790
ALA A 625
TYR A 458
1.39A12.85
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3L2V_A_RLTA397_1
(INTEGRASE)		7bv1 NSP12
NSP7
(SARS-CoV-2)		4 / 7
ASP A 445
GLN C  18
TYR A 546
GLN A 408
1.68A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4MDA_A_RLTA403_1
(MARINER MOS1
TRANSPOSASE)		7bv1 NSP12
(SARS-CoV-2)		4 / 6
ASP A  36
ALA A  46
TYR A 129
ASP A 208
1.76A12.85
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4MDB_A_RLTA401_1
(MARINER MOS1
TRANSPOSASE)		7bv1 NSP12
(SARS-CoV-2)		4 / 6
ASN A 507
ALA A 502
TYR A 515
ASP A 499
1.67A12.85
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3L2V_A_RLTA397_1
(INTEGRASE)		7bv2 NSP12
NSP7
(SARS-CoV-2)		4 / 7
ASP A 445
GLN C  18
TYR A 546
GLN A 408
1.61A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4MDB_A_RLTA401_1
(MARINER MOS1
TRANSPOSASE)		7bv2 NSP12
(SARS-CoV-2)		4 / 6
ASN A 507
ALA A 502
TYR A 515
ASP A 499
1.47A12.85
 U  T   8 ( 3.5A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4MDB_A_RLTA401_1
(MARINER MOS1
TRANSPOSASE)		7bv2 NSP12
(SARS-CoV-2)		4 / 6
ASP A 221
ASN A  39
ALA A  43
TYR A  38
1.79A12.85
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4MDB_A_RLTA401_1
(MARINER MOS1
TRANSPOSASE)		7bv2 NSP12
(SARS-CoV-2)		4 / 6
ASP A 126
ALA A 130
TYR A 129
ASP A 208
1.63A12.85
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3OYA_A_RLTA398_1
(PFV INTEGRASE)		7bv2 NSP12
(SARS-CoV-2)		4 / 8
PRO A 834
TYR A 877
GLN A 815
GLU A 811
1.78A
None
None
A  P  19 ( 4.9A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4MDA_A_RLTA403_1
(MARINER MOS1
TRANSPOSASE)		7bv2 NSP12
(SARS-CoV-2)		4 / 6
ASP A 126
ALA A 130
TYR A 129
ASP A 208
1.67A12.85
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3OYA_A_RLTA398_1
(PFV INTEGRASE)		7bv2 NSP12
NSP7
(SARS-CoV-2)		4 / 8
ASP A 445
GLN C  18
TYR A 546
GLN A 408
1.42A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4MDB_A_RLTA401_1
(MARINER MOS1
TRANSPOSASE)		7bv2 NSP12
(SARS-CoV-2)		4 / 6
ASP A  36
ALA A  46
TYR A 129
ASP A 208
1.75A12.85
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4MDA_A_RLTA403_1
(MARINER MOS1
TRANSPOSASE)		7bv2 NSP12
(SARS-CoV-2)		4 / 6
ASP A  36
ALA A  46
TYR A 129
ASP A 208
1.77A12.85
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4MDA_A_RLTA403_1
(MARINER MOS1
TRANSPOSASE)		7bv2 NSP12
(SARS-CoV-2)		4 / 6
ASP A 623
ALA A 625
TYR A 458
ASP A 452
1.65A12.85
POP  A1003 ( 3.5A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4MDB_A_RLTA401_1
(MARINER MOS1
TRANSPOSASE)		7bv2 NSP12
(SARS-CoV-2)		4 / 6
ASN A  39
ALA A  43
TYR A 728
ASP A 208
1.42A12.85
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4MDB_A_RLTA401_1
(MARINER MOS1
TRANSPOSASE)		7bv2 NSP12
(SARS-CoV-2)		4 / 6
ASP A 208
ASN A  39
ALA A  43
TYR A 728
1.69A12.85
None